Globalagliatin

Globalagliatin
Clinical data
Other names	SY-004
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (1R,2S)-2-Cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide;
CAS Number	1234703-40-2;
PubChem CID	46832368;
DrugBank	DB12284;
ChemSpider	26323625;
UNII	5A0L003HEY;
ChEMBL	ChEMBL4297399;
Chemical and physical data
Formula	C28H37N3O3S3
Molar mass	559.80 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6;
	InChI InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1; Key:QIIVJLHCZUTGSD-CUBQBAPOSA-N;

Globalagliatin (SY-004) is a glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes.^[1]^[2]^[3]

References

↑ Zhao, Yuqing; Xie, Lijun; Zhang, Hongwen; Zhou, Sufeng; Liu, Yun; Chen, Juan; Wang, Lu; Wang, Libin; Zhuo, Lang; Wang, Yarong; Ou, Ning; Shao, Feng (February 2022). "Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study". Clinical Therapeutics. 44 (2): 269–281. doi:10.1016/j.clinthera.2021.12.009. PMID 35093240. S2CID 246416557.
↑ Zheng, Shuai; Shao, Feng; Ding, Yu; Fu, Zhenzhen; Fu, Qi; Ding, Sijia; Xie, Lijun; Chen, Juan; Zhou, Sufeng; Zhang, Hongwen; Zhou, Hongwen; Chen, Yang; Sun, Caixia; Zhu, Jing; Zheng, Xuqin; Yang, Tao (December 2020). "Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study". Clinical Drug Investigation. 40 (12): 1155–1166. doi:10.1007/s40261-020-00971-x. PMID 33125674. S2CID 225983121.
↑ Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Jiao, Ruoyang; Ji, Linong (8 May 2023). "Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis". Frontiers in Endocrinology. 14 1175198. doi:10.3389/fendo.2023.1175198. PMC 10200948. PMID 37223016.